KR100538721B1 - 항미생물제로서의 플레우로뮤틸린 유도체 - Google Patents

항미생물제로서의 플레우로뮤틸린 유도체 Download PDF

Info

Publication number
KR100538721B1
KR100538721B1 KR10-2000-7004707A KR20007004707A KR100538721B1 KR 100538721 B1 KR100538721 B1 KR 100538721B1 KR 20007004707 A KR20007004707 A KR 20007004707A KR 100538721 B1 KR100538721 B1 KR 100538721B1
Authority
KR
South Korea
Prior art keywords
mol
acetate
title compound
nmr
cdcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR10-2000-7004707A
Other languages
English (en)
Korean (ko)
Other versions
KR20010031654A (ko
Inventor
발러리 베리
스테픈 답스
콜린 헨리 프리드리히
에릭 헌트
게리 우드넛
프란시스 도미닉 샌더슨
Original Assignee
스미스클라인비이참피이엘시이
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26312507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100538721(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9722817.5A external-priority patent/GB9722817D0/en
Priority claimed from GBGB9813689.8A external-priority patent/GB9813689D0/en
Application filed by 스미스클라인비이참피이엘시이, 스미스클라인 비참 코포레이션 filed Critical 스미스클라인비이참피이엘시이
Publication of KR20010031654A publication Critical patent/KR20010031654A/ko
Application granted granted Critical
Publication of KR100538721B1 publication Critical patent/KR100538721B1/ko
Assigned to 글락소 그룹 리미티드 reassignment 글락소 그룹 리미티드 권리의 전부이전등록 Assignors: 스미스클라인 비참 코포레이션, 스미스클라인비이참피이엘시이
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/36—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
KR10-2000-7004707A 1997-10-29 1998-10-27 항미생물제로서의 플레우로뮤틸린 유도체 Expired - Lifetime KR100538721B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9722817.5A GB9722817D0 (en) 1997-10-29 1997-10-29 Novel compounds
GB9722817.5 1997-10-29
GB9813689.8 1998-06-25
GBGB9813689.8A GB9813689D0 (en) 1998-06-25 1998-06-25 Novel compounds
PCT/GB1998/003211 WO1999021855A1 (en) 1997-10-29 1998-10-27 Pleuromutilin derivatives as antimicrobials

Publications (2)

Publication Number Publication Date
KR20010031654A KR20010031654A (ko) 2001-04-16
KR100538721B1 true KR100538721B1 (ko) 2005-12-26

Family

ID=26312507

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7004707A Expired - Lifetime KR100538721B1 (ko) 1997-10-29 1998-10-27 항미생물제로서의 플레우로뮤틸린 유도체

Country Status (35)

Country Link
US (3) US6281226B1 (https=)
EP (3) EP1028961B3 (https=)
JP (2) JP4227729B2 (https=)
KR (1) KR100538721B1 (https=)
CN (1) CN1205211C (https=)
AR (1) AR015987A1 (https=)
AT (2) ATE525373T1 (https=)
AU (1) AU742167C (https=)
BR (1) BR9814747B1 (https=)
CA (1) CA2307551C (https=)
CO (1) CO5021129A1 (https=)
CY (2) CY2007028I2 (https=)
CZ (1) CZ298543B6 (https=)
DE (2) DE69826704T3 (https=)
DK (2) DK1028961T5 (https=)
DZ (1) DZ2634A1 (https=)
EG (1) EG24177A (https=)
ES (2) ES2229538T7 (https=)
FR (1) FR07C0057I2 (https=)
HU (2) HU229792B1 (https=)
IL (2) IL135811A0 (https=)
LU (1) LU91372I2 (https=)
MY (1) MY130665A (https=)
NL (1) NL300304I2 (https=)
NO (3) NO327392B1 (https=)
NZ (1) NZ504203A (https=)
PE (1) PE123299A1 (https=)
PL (2) PL191927B1 (https=)
PT (2) PT1930330E (https=)
SI (2) SI1028961T1 (https=)
TR (1) TR200001203T2 (https=)
TW (1) TWI232861B (https=)
UY (1) UY25225A1 (https=)
WO (1) WO1999021855A1 (https=)
ZA (1) ZA989767B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
WO2000027790A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
GB9912657D0 (en) * 1999-06-01 1999-07-28 Smithkline Beecham Plc Novel compounds
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
GB9919839D0 (en) * 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE60139382D1 (de) * 2000-04-04 2009-09-10 Smithkline Beecham Plc 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
GB0017073D0 (en) * 2000-07-11 2000-08-30 Univ London Microorganism
GB0017031D0 (en) 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
PE20020676A1 (es) * 2000-09-13 2002-08-27 Biochemie Gmbh Compuestos de mutilina como antibacterianos
GB0024811D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0027705D0 (en) 2000-11-11 2000-12-27 S P A Novel compounds
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
GB0207495D0 (en) * 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
DE60317208T2 (de) * 2002-07-24 2008-08-07 Nabriva Therapeutics Forschungs Gmbh Pleuromutilinderivate als antimikrobielle mittel
GB0218578D0 (en) * 2002-08-09 2002-09-18 Glaxo Group Ltd Novel method
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
EP1663220B1 (en) * 2003-09-03 2009-12-02 Glaxo Group Limited Novel process for the preparation of pleuromutilin derivatives
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0504314D0 (en) * 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
EP1860943A4 (en) * 2005-03-10 2008-06-18 Smithkline Beecham Corp NOVEL PROCEDURE
US7790767B2 (en) * 2005-06-27 2010-09-07 Nabriva Therapeutics Forschungs Gmbh Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0513058D0 (en) * 2005-06-27 2005-08-03 Sandoz Ag Organic compounds
WO2007037518A1 (ja) * 2005-09-29 2007-04-05 Dainippon Sumitomo Pharma Co., Ltd. ムチリン誘導体及びそれを含有する医薬組成物
WO2007079173A2 (en) * 2005-12-30 2007-07-12 Emergent Biosolutions Inc. Novel 2-heteroaryloxy-phenol derivatives as antibacterial agents
EP2119716A4 (en) 2007-02-09 2011-06-01 Astellas Pharma Inc AZA BRIDGE CYCLE COMPOUND
WO2008117796A1 (ja) * 2007-03-28 2008-10-02 Dainippon Sumitomo Pharma Co., Ltd. 新規ムチリン誘導体
JP5322927B2 (ja) 2007-05-24 2013-10-23 杏林製薬株式会社 １４位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体
US20090076071A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched retapamulin
US20090234125A1 (en) * 2007-11-26 2009-09-17 Eli Lancry Amorphous retapamulin and processes for preparation thereof
WO2009075776A1 (en) * 2007-12-05 2009-06-18 Teva Pharmaceutical Industries Ltd. Process for the preparation of retapamulin and its intermediates
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
WO2010056855A1 (en) * 2008-11-13 2010-05-20 Teva Pharmaceutical Industries Ltd. Preparation of retapamulin via its pleuromutilin-thiol precursor
JP5422821B2 (ja) * 2009-03-03 2014-02-19 独立行政法人放射線医学総合研究所 コリンエステラーゼ活性測定用試薬
WO2011008572A2 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
CN102344397B (zh) * 2011-08-23 2013-09-04 浙江升华拜克生物股份有限公司 一种伐奈莫林盐酸盐的提纯方法
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
CN103709093B (zh) * 2012-09-28 2016-06-08 山东亨利医药科技有限责任公司 含有并环的截短侧耳素类抗生素
WO2016014581A1 (en) 2014-07-21 2016-01-28 Endochoice, Inc. Multi-focal, multi-camera endoscope systems
CN109195608B (zh) * 2016-03-02 2021-05-11 比尔及梅琳达盖茨基金会 含硼小分子
WO2017151492A1 (en) * 2016-03-02 2017-09-08 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
CN106496085B (zh) * 2016-09-21 2018-01-26 盐城市舜宝化工有限公司 合成盐酸沃尼妙林的中间体化合物以及盐酸沃尼妙林的制备方法
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
CN111574395B (zh) * 2020-06-18 2021-07-02 华南农业大学 一种具有酰胺侧链的截短侧耳素衍生物及制备与应用
AT523646B1 (de) 2020-07-21 2021-10-15 Gerd Dr Ascher Pharmazeutische Verbindungen, ihre Anwendung alleine oder in Kombination, zur Prophylaxe und lokalen Initial-Therapie bei bakteriellen und viralen Infektionen, insbesondere Coronaviren
US11155514B1 (en) * 2020-12-19 2021-10-26 Shaanxi University Of Science And Technology Pleuromulin acitretin ester with antibacterial activity and a method of preparing the same
US11332430B1 (en) * 2021-01-25 2022-05-17 Xi'an Taikomed Pharmaceutical Technology Co., Ltd. Pleuromulin lauric acid ester with antibacterial activity and a method of preparing the same
CN112919463B (zh) * 2021-04-09 2021-10-26 南京理工大学 一种利用泰妙菌素废盐制备的活性炭及其制备方法
CN113121355B (zh) * 2021-04-13 2023-05-09 西安康诺化工有限公司 一种截短侧耳素大黄酸酯及其制备方法和应用
CN114736194A (zh) * 2022-03-29 2022-07-12 中牧实业股份有限公司 一种具有抗病原微生物活性的含吡啶季铵盐侧链的截短侧耳素衍生物及其制备方法与应用
CN119930551B (zh) * 2024-04-28 2026-04-07 徐士新 一种截短侧耳素衍生物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0013768A1 (en) * 1979-01-12 1980-08-06 Sandoz Ag New pleuromutilin derivatives, their production and pharmaceutical compositions containing them

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060542A (en) * 1969-07-25 1977-11-29 Biochemie Gesellschaft M.B.H. 14-Desoxy-14 thiocyanato-acetoxy-mutilin
US4208326A (en) 1971-10-05 1980-06-17 Sandoz Ltd. Pleuromutilin esters
BE789629A (fr) * 1971-10-05 1973-04-03 Sandoz Sa Nouveaux derives de la pleuromutiline, leur preparation et leurapplication en therapeutique
US3919290A (en) 1972-10-03 1975-11-11 Sandoz Ltd Substituted 14-desoxy-mutilins
US4032530A (en) 1971-10-05 1977-06-28 Sandoz Ltd. Certain pleuromutilins
CH575375A5 (https=) 1972-05-25 1976-05-14 Sandoz Ag
CH593912A5 (en) 1972-07-07 1977-12-30 Sandoz Ag Pleuromutilin derivs. - prepd. by acylating derivs. contg. a (4)-hydroxyalkyl-(1)-piperazinyl gp.
DE2404046C3 (de) 1974-01-29 1984-07-26 Henkel KGaA, 4000 Düsseldorf Verwendung von Carboxyl- bzw. Carboxylat- und Hydroxylgruppen aufweisenden Polymeren als Hautfeuchthaltemittel
US3987194A (en) 1975-05-12 1976-10-19 E. R. Squibb & Sons, Inc. Use of pleuromutilin derivatives for the treatment of swine dysentery
CH619450A5 (https=) 1976-01-15 1980-09-30 Sandoz Ag
US4130709A (en) 1977-12-08 1978-12-19 Eli Lilly And Company Pleuromutilin glycoside derivatives
GB2025930B (en) 1978-06-01 1983-02-09 Sandoz Ltd Process for the production of pleuromutilin derivatives
JPS5594359A (en) * 1979-01-12 1980-07-17 Sandoz Ag Novel pleuromutilin derivatives*their manufacture and use
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
DE3560511D1 (en) * 1984-02-17 1987-10-01 Sandoz Ag Pleuromutilin derivatives, process for their preparation and their use
DE3405632A1 (de) * 1984-02-17 1985-08-22 Sandoz-Patent-GmbH, 7850 Lörrach Neue pleuromutilinderivate, verfahren zu ihrer herstellung und ihre verwendung
AT400674B (de) 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
AT397654B (de) 1992-05-04 1994-06-27 Biochemie Gmbh Neue pleuromutilinderivate, ihre verwendung und verfahren zu ihrer herstellung
EP0799202A1 (de) 1994-12-23 1997-10-08 Dr. Karl Thomae GmbH Piperazinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JP4163254B2 (ja) * 1996-01-03 2008-10-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ムチリンのカルバモイルオキシ誘導体および抗細菌剤としてのそれらの使用
HUP0001741A3 (en) 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
CZ112499A3 (cs) 1996-10-01 1999-08-11 Smithkline Beecham Corporation Použití mupirocinu k výrobě léčiva pro léčbu bakteriálních infekcí spojených s kolonizací nosohltanu patogenními organismy
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
EP1663220B1 (en) 2003-09-03 2009-12-02 Glaxo Group Limited Novel process for the preparation of pleuromutilin derivatives
GB0504314D0 (en) 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0013768A1 (en) * 1979-01-12 1980-08-06 Sandoz Ag New pleuromutilin derivatives, their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO20091344L (no) 2000-06-05
CA2307551C (en) 2007-01-30
NO20002173D0 (no) 2000-04-27
DK1028961T3 (da) 2005-01-03
US6281226B1 (en) 2001-08-28
DE122007000076I1 (de) 2008-02-14
NO20002173L (no) 2000-06-05
DE69826704D1 (de) 2004-11-04
PL191927B1 (pl) 2006-07-31
BR9814747B1 (pt) 2010-12-14
PL197672B1 (pl) 2008-04-30
DE69826704T2 (de) 2005-10-06
HUP0004040A1 (hu) 2001-05-28
IL135811A0 (en) 2001-05-20
AU742167C (en) 2003-08-07
LU91372I2 (fr) 2007-12-24
AU742167B2 (en) 2001-12-20
NL300304I1 (nl) 2008-01-02
LU91372I9 (https=) 2019-01-02
PT1028961E (pt) 2005-01-31
WO1999021855A1 (en) 1999-05-06
ES2229538T7 (es) 2009-06-18
ATE525373T1 (de) 2011-10-15
FR07C0057I2 (fr) 2008-05-16
EP1028961B1 (en) 2004-09-29
AR015987A1 (es) 2001-05-30
USRE39128E1 (en) 2006-06-13
FR07C0057I1 (https=) 2007-12-14
HU229792B1 (en) 2014-07-28
EP1028961A1 (en) 2000-08-23
SI1028961T1 (en) 2005-02-28
ES2371205T3 (es) 2011-12-28
CZ298543B6 (cs) 2007-10-31
CY1112062T1 (el) 2015-11-04
CN1283197A (zh) 2001-02-07
EP1028961B3 (en) 2008-12-03
NO2009023I1 (no) 2009-10-12
UY25225A1 (es) 2000-12-29
CO5021129A1 (es) 2001-03-27
NL300304I2 (nl) 2008-03-03
AU9636198A (en) 1999-05-17
EP1930330B1 (en) 2011-09-21
IL135811A (en) 2006-12-31
MY130665A (en) 2007-07-31
DZ2634A1 (fr) 2003-03-08
NZ504203A (en) 2002-11-26
CY2007028I1 (el) 2009-11-04
DK1028961T5 (da) 2009-03-09
HK1031376A1 (en) 2001-06-15
JP4227729B2 (ja) 2009-02-18
EG24177A (en) 2008-09-28
DK1930330T3 (da) 2011-12-12
CA2307551A1 (en) 1999-05-06
TR200001203T2 (tr) 2000-08-21
PL340254A1 (en) 2001-01-29
CY2007028I2 (el) 2009-11-04
DE69826704T3 (de) 2009-07-23
HUS1400060I1 (hu) 2016-09-28
ATE277925T1 (de) 2004-10-15
ES2229538T3 (es) 2005-04-16
JP2009040789A (ja) 2009-02-26
PT1930330E (pt) 2011-10-31
PE123299A1 (es) 2000-02-05
EP1930330A1 (en) 2008-06-11
USRE43390E1 (en) 2012-05-15
NO2009023I2 (no) 2012-12-03
DE122007000076I2 (de) 2010-03-25
ZA989767B (en) 2000-04-28
TWI232861B (en) 2005-05-21
SI1930330T1 (sl) 2011-12-30
JP2001521033A (ja) 2001-11-06
KR20010031654A (ko) 2001-04-16
CZ20001551A3 (cs) 2001-01-17
NO327392B1 (no) 2009-06-22
HUP0004040A3 (en) 2001-08-28
EP1452534A1 (en) 2004-09-01
CN1205211C (zh) 2005-06-08
BR9814747A (pt) 2001-11-20

Similar Documents

Publication Publication Date Title
KR100538721B1 (ko) 항미생물제로서의 플레우로뮤틸린 유도체
JP5038509B2 (ja) β−ラクタマーゼ阻害剤
JPH05320162A (ja) ペプチド性キヌクリジン
US7045524B2 (en) Pleuromutilin derivatives with antimicrobial activity
EP0559774B1 (en) Individual stereoisomers of 7- 3-(1-aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents
JP2002522409A (ja) ２−フルオロムチリン誘導体
HK1071128A (en) Pleuromutlin derivatives as antimicrobials
HK1031376B (en) Pleuromutilin derivatives as antimicrobials
MXPA00004202A (en) Pleuromutilin derivatives as antimicrobials
HK1116784A (en) Pleuromutilin derivatives as antimicrobials

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000429

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030924

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050530

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20051114

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051219

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051220

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081014

Start annual number: 4

End annual number: 4

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20091009

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

PR1001 Payment of annual fee

Payment date: 20091016

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101129

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20111129

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121129

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121129

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131129

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131129

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20141128

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20141128

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20161125

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20161125

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20170929

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20170929

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20180928

Start annual number: 14

End annual number: 14

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20200220

Termination category: Expiration of duration